PROKIDNEY CORP.

ProKidney Corp. (Nasdaq: DNAC) is a clinical-stage biotherapeutics company focused on treating chronic kidney disease through regenerative cell therapy. The company became publicly traded in 2022 following a business combination with Social Capital Suvretta Holdings Corp. IV, a blank-check vehicle sponsored by Social Capital and Suvretta Capital Management that completed its IPO in 2021. ProKidney's lead program, REACT (Renal Autologous Cell Therapy), is designed to use a patient's own kidney cells to slow disease progression. The 10-Q filed August 12, 2022 captures the company's early post-merger operating period in the healthcare and biotechnology sector. Sign up on SpacDesk for full filings, sponsor data, and analytics on ProKidney and the broader SPAC universe.